Amitech Therapeutic Solutions
Targeting Specific Cancers with Immunotherapy
Amitech Therapeutic Solutions, Inc. (ATS), is a virtual drug discovery and development company based in La Jolla, CA, that has a close working relationship with the Moores Cancer Center at the University of California, San Diego. Their focus is immunology – using pharmaceutical therapies to activate or suppress the immune system to fight different types of cancer.
North America is the largest immunotherapy market in the world, at $163B, and is expected to grow to more than $275B by 2025.
To meet this need, Amitech has developed, OncArrest, a highly targetable, therapeutic platform for Melanoma, Colorectal Cancer, Lung Cancer, and others. It works by replacing pro-tumor macrophages with anti-tumor macrophages using a therapeutic.
OncArrest is a tunable kinase inhibitor platform paired with a tumor-targeting, nano-particle delivery system. Their lead compound, 3G-8, has shown significant results in small animal tests. The nano-particle delivery system encapsulates the molecules and targets tumors via the Enhanced Permeability and Retention (EPR) effect. This means the molecules go directly to the tumor and are time released, increasing the drug’s efficacy and reducing its toxicity.
Once in the tumor, 3G-8 converts the tumor microenvironment from “cold” to “hot” allowing for immune cell infiltration and tumor destruction. In addition, 3G-8 can be modified with new combinations to extend the molecule’s patent life. Amitech is in the process of seeking an IND from the FDA for OncArrest.
Amitech is led by CEO, Mark Bertagnolli who has spent the last 15 years in various roles in the investment community, following several years in the technology industry, serving first as an analyst at Andor Capital, and then as portfolio manager at Morgan Stanley. Mr. Bertagnolli served as Chief Business officer of Genelux Corporation, a San Diego start-up focused on oncology therapies. While serving on active duty in the US Nuclear Submarine Force from 1990 to 1995, Mr. Bertagnolli qualified as a Navy Nuclear Engineering Officer, certified by the Department of Energy. He holds a B.S. in Aerospace Engineering from the University of Michigan, Ann Arbor.
Robert A. Galemmo, Jr., PhD., Chief Scientific Officer is a creative medicinal chemist, scientific and managerial leader with over 30 years’ experience in the pharmaceutical and biotech industry. Under his leadership, drug discovery teams have produced multiple clinical and development candidates. While with DuPont Merck Pharmaceuticals he initiated the medicinal chemistry program that led to the marketed factor Xa oral anti-coagulant Apixaban/Eliquis®. At Johnson & Johnson, he led the team that discovered the clinical cMet oncology agent JNJ 38877605. Dr. Galemmo’s broad therapeutic area experience includes CNS, oncology, cardiovascular, inflammation, and gastrointestinal. He is an inventor on over 40 patents and an author of more than 50 scientific publications. Dr. Galemmo received his PhD in Organic Chemistry from the Ohio State University.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.